Research Funding

National Heart, Lung, Blood Institute R01 07/01/2020-06/30/2025

National Institutes of Health

Role of suPAR in the Intersection between Cardiovascular and Kidney Disease

To investigate suPAR as a pathogenic factor for cardiovascular disease and probe current and potential treatments and preventative interventions.

National Institute of Diabetes and Digestive and Kidney Diseases 09/01/2021-08/31/2024

National Institutes of Health

Extracorporeal SuPAR Extraction to Prevent COVID-19 Associated Acute Kidney Injury

Proposal aims to assess the safety and efficacy of extracting and measuring suPAR levels via apheresis as a prevention strategy for COVID-19-associated Acute Kidney Injury (AKI).

Roche Diagnostics Investigator Initiated Study 03/01/2022-02/28/2023

Role of Cardiovascular Biomarkers in the Prognostication and Identification of Immune Checkpoint Inhibitor Myocarditis

Proposal aims to assess the clinical utility of cardiac and inflammatory blood-based biomarker measurements in the management of patients receiving ICI treatment.

Rogel Cancer Center Discovery Award & R01 Accelerator 11/01/2021-01/31/2023

Cardiovascular Complications of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): Creating Evidence-based Strategies for the Pre-Transplant Cardiovascular Evaluation

Defining incidence and predictors of CVD outcomes in patients undergoing HSCT to devise evidence-based strategies and criteria for pre-transplant risk stratification, optimization of CV health prior to therapy, and safe HSCT process and survivorship.

Ortho Clinical Diagnostics 10/28/2021 - 10/27/2022

Effective Triage of Patients Presenting with COVID-19

Project aims to distinguish risks events associated with specific inflammatory biomarkers in patients hospitalized for COVID-19.

Completed Funding

Gilead Research Scholar - Cardiovascular Comorbidities 10/01/2020-09/30/2022

Gilead Sciences Research Scholars Program

Deciphering the "suPAR" Pathway of Atherosclerosis: The Link Between the Heart, Kidneys, and Immune System

This project aims to decipher a pathogenic role for suPAR in atherosclerosis utilizing an adeno-associated viral vector murine model of disease, and to lay the groundwork for developing greatly needed therapies to reduce the progression of atherosclerosis in the setting of kidney disease.

National Institutes of Health 07/28/2021-07/27/2022

MICHR Catalyst

Use of Soluble Urokinase Plasminogen Activator Receptor to Define High-risk HFpEF and Guide Spironolactone Therapy

Findings of this study will determine whether suPAR levels could be used to identify patients who would benefit from spironolactone, and whether suPAR should be incorporated into the eligibility criteria of trials assessing the benefits of HFpEF therapies.

National Institute of Diabetes and Digestive and Kidney Diseases 03/31/2020-03/30/2022

National Institutes of Health

The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2

This project aims to identify COVID-19 outpatients eligible to participate in prospective KIDCOV study, assess long-term urine kidney injury among patients, and coordinate analysis of KIDCOV EMR data between USCF Data Coordinating Center and the AMC.

Health and Human Services 06/01/2021-12/31/2022

National Institutes of Health

MICHR Catalyst Trial

Project aims to compare suPAR levels in patients who suffer from heart failure with preserved ejection fraction (HFpEF) to determine the efficacy of spironolactone drug therapy.

Frankel Cardiovascular Center COVID-19 Ignitor Grant 04/01/2020-12/31/2021

Frankel Cardiovascular Center

Effective Triaging of Patients with Suspected Covid-19 Using suPAR

To determine whether suPAR can be used to triage patients presenting with suspected Covid-19 respiratory symptoms; differentiating those who are more likely to have progressive disease and require a higher level of care.

National Institute of Diabetes and Digestive and Kidney Diseases 10/01/2020-12/31/2021

National Institutes of Health

DFU Clinical Research Unit COVID19 Supplemental Grant

Project goals are to ascertain in-hospital outcomes and inflammatory signatures within the entire M2C2, to deep phenotype M2C2 participants post-hospitalization to chronic vascular complications (DKD, DN and CVD), and inflammatory signatures, and to assess the post-hospitalization psychosocial outcomes of M2C2 participants.

Frankel Cardiovascular Center Research Amplifier Grant 01/01/2020-12/31/2020

Frankel Cardiovascular Center

Deciphering the “suPAR” Pathway of Atherosclerosis

To determine whether suPAR plays a causal role in the pathogenesis of atherosclerosis using histological and immunofluorescence techniques in tissue from suPAR overexpressing mice with genetically induced atherosclerosis

MI-Kickstart Grant 09/27/2019-09/26/2020

MTRAC for Life Sciences Innovation Hub

Using a ‘suPAR’ Biomarker to Guide the Management of Multi-vessel Coronary Artery Disease

To derive an appropriate cut-off level for the circulating biomarker suPAR and associated clinical algorithm in patients with high-risk coronary disease to identify patients with multi-vessel coronary artery disease who would preferentially benefit from percutaneous coronary intervention rather than undergo coronary artery bypass surgery. State of Michigan Economic Development Program.

MICHR Grant 08/01/2019-07/31/2020

Michigan Insitute for Clinical and Health Research

Characterizing a 'suPAR' Biomarker of Risk: Soluble Urokinase Plasminogen Activator Receptor and Subclinical Markers Of Atherosclerosis

To examine the correlation of suPAR levels with subclinical markers and progression of atherosclerosis, independently of declining kidney function, and improve the risk discrimination beyond conventional cardiovascular biomarkers and risk factors in a sample of the general population in the Multi-Ethnic Study of Atherosclerosis (MESA.) 5 UL1 TR002240-03

MDDFAD Grant 07/01/2019-06/30/2020

NIH/Michigan Center for Contextual Factors in Alzheimer’s Disease

Using a “SuPAR” Biomarker to Evaluate the Burden of Inflammation and its Impact on the Ethnoracial Differences in Cognitive Decline

Characterizing levels of soluble urokinase plasminogen activator receptor (suPAR) – a novel marker of chronic immune activation – in patients with AD, determine whether levels can predict declining cognitive function, and assess whether differences in the burden of inflammation accounts for ethnoracial differences in cognitive decline. 5 P30 AG059300-02

McKay Grant 02/01/2019-01/31/2020

UM Frankel Cardiovascular Center

Genetic Determinants and Heritability of Soluble Urokinase Plasminogen Activator Receptor

The overarching objective of this proposal is to improve our understanding of the genetic and environmental factors that regulate suPAR. Precise estimation of the heritability of suPAR will clarify how much of the population variation is due to genetic factors.